Search
Veru Inc
VERUAdd to Watchlist
2.975USD
+0.025+0.85%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
47.75MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Veru Inc is 9.00, ranking 14 out of 389 in the Biotechnology & Medical Research industry. The average price target is 22.50, with a high of 30.00 and a low of 10.00.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
24.500
Target Price
+730.51%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Veru Inc
VERU
2
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Veru Inc's price target?
Analysts forecast that Veru Inc's price target is USD 22.50, with the highest forecast at USD 30.00 and the lowest forecast at USD 10.00.
How have Veru IncVERU's recent earnings per share performed?
The market expectation was USD -0.12, while Veru IncVERU's earnings per share (EPS) for the previous quarter was USD -0.26. EPS for the next quarter is expected at USD -0.32.
What is the analyst rating for Veru Inc?
Based on the ratings of Veru Inc's stock from 2 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.
